Abstract
Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remission rates, diseasefree survival and overall survival, all achieved with minimal toxicity. Bevacizumab, a humanized monoclonal antiantibody with anti-angiogenetic properties through inhibition of vascular endothelial growth factor, was initially approved for the adjuvant treatment of metastatic colorectal cancer with promising results. Eculizumab, a selective inhibitor of the complement terminal cascade, was the first etiologic treatment of intravascular hemolysis in patients with the rare, acquired paroxysmal nocturnal hemoglobinuria (PNH). Although none of these agents has direct antithrombotic properties, there is increasing evidence of their preemptive and therapeutic use in rare acquired thrombotic disorders, including thrombotic thrombocytopenic purpura (TTP), central retinal vein occlusion (CRVO) and PNH-associated thrombophilia. This brief review aims to discuss hopes and pitfalls of these new approaches in the context of the underlying mechanisms that lead to thrombosis in these disorders.
Keywords: Thrombosis, eculizumab, rituximab, bevacizumab, retinal vein, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura
Current Vascular Pharmacology
Title: Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Volume: 8 Issue: 1
Author(s): Panayiotis D. Ziakas, Petros Kopterides and Michael Voulgarelis
Affiliation:
Keywords: Thrombosis, eculizumab, rituximab, bevacizumab, retinal vein, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura
Abstract: Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remission rates, diseasefree survival and overall survival, all achieved with minimal toxicity. Bevacizumab, a humanized monoclonal antiantibody with anti-angiogenetic properties through inhibition of vascular endothelial growth factor, was initially approved for the adjuvant treatment of metastatic colorectal cancer with promising results. Eculizumab, a selective inhibitor of the complement terminal cascade, was the first etiologic treatment of intravascular hemolysis in patients with the rare, acquired paroxysmal nocturnal hemoglobinuria (PNH). Although none of these agents has direct antithrombotic properties, there is increasing evidence of their preemptive and therapeutic use in rare acquired thrombotic disorders, including thrombotic thrombocytopenic purpura (TTP), central retinal vein occlusion (CRVO) and PNH-associated thrombophilia. This brief review aims to discuss hopes and pitfalls of these new approaches in the context of the underlying mechanisms that lead to thrombosis in these disorders.
Export Options
About this article
Cite this article as:
Ziakas D. Panayiotis, Kopterides Petros and Voulgarelis Michael, Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226651
DOI https://dx.doi.org/10.2174/157016110790226651 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Lipid Nanocarriers (LNC) and their Applications in Ocular Drug Delivery
Current Medicinal Chemistry